Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0–2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance?
- 29 February 2004
- journal article
- Published by Elsevier BV in Urologic Oncology
- Vol. 22 (1), 40-47
- https://doi.org/10.1016/s1078-1439(03)00093-0
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Prostate-specific antigen best practice policy—part I: early detection and diagnosis of prostate cancerUrology, 2001
- European randomized study of prostate cancer screening: first-year results of the Finnish trialBritish Journal of Cancer, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- CHARACTERISTICS OF SCREENING DETECTED PROSTATE CANCER IN MEN 50 TO 66 YEARS OLD WITH 3 TO 4 NG./ML. PROSTATE SPECIFIC ANTIGENJournal of Urology, 1998
- Prostate carcinoma screening in the county of Tyrol, AustriaCancer, 1997
- Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurementsJAMA, 1997
- Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancerCancer, 1993
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerThe New England Journal of Medicine, 1991
- Prostate Cancer Detection in a Clinical Urological Practice by Ultrasonography, Digital Rectal Examination and Prostate Specific AntigenJournal of Urology, 1990
- Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical StagingJournal of Urology, 1974